Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Civeo (CVEO) Assets (2016 - 2025)

Civeo has reported Assets over the past 13 years, most recently at $477.4 million for Q4 2025.

  • Quarterly results put Assets at $477.4 million for Q4 2025, up 17.86% from a year ago — trailing twelve months through Dec 2025 was $477.4 million (up 17.86% YoY), and the annual figure for FY2025 was $477.4 million, up 17.86%.
  • Assets for Q4 2025 was $477.4 million at Civeo, down from $491.1 million in the prior quarter.
  • Over the last five years, Assets for CVEO hit a ceiling of $717.7 million in Q2 2021 and a floor of $405.1 million in Q4 2024.
  • Median Assets over the past 5 years was $553.9 million (2023), compared with a mean of $562.0 million.
  • Biggest five-year swings in Assets: dropped 26.09% in 2024 and later grew 17.86% in 2025.
  • Civeo's Assets stood at $672.7 million in 2021, then fell by 15.84% to $566.2 million in 2022, then fell by 3.2% to $548.1 million in 2023, then dropped by 26.09% to $405.1 million in 2024, then increased by 17.86% to $477.4 million in 2025.
  • The last three reported values for Assets were $477.4 million (Q4 2025), $491.1 million (Q3 2025), and $508.8 million (Q2 2025) per Business Quant data.